Cargando…

Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study

SIMPLE SUMMARY: Advanced thymic carcinoma (ATC) is rare. Owing to its rarity, there is limited information on the prognostic factors, and the optimal serum tumor markers are also unknown. We conducted a multi-institutional retrospective study of patients with ATC. In this study, we collected data on...

Descripción completa

Detalles Bibliográficos
Autores principales: Mimori, Tomoyasu, Shukuya, Takehito, Ko, Ryo, Okuma, Yusuke, Koizumi, Tomonobu, Imai, Hisao, Takiguchi, Yuichi, Miyauchi, Eisaku, Kagamu, Hiroshi, Sugiyama, Tomohide, Azuma, Keisuke, Namba, Yukiko, Yamasaki, Masahiro, Tanaka, Hisashi, Takashima, Yuta, Soda, Sayo, Ishimoto, Osamu, Koyama, Nobuyuki, Kobayashi, Kunihiko, Takahashi, Kazuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773938/
https://www.ncbi.nlm.nih.gov/pubmed/35053494
http://dx.doi.org/10.3390/cancers14020331
_version_ 1784636221076537344
author Mimori, Tomoyasu
Shukuya, Takehito
Ko, Ryo
Okuma, Yusuke
Koizumi, Tomonobu
Imai, Hisao
Takiguchi, Yuichi
Miyauchi, Eisaku
Kagamu, Hiroshi
Sugiyama, Tomohide
Azuma, Keisuke
Namba, Yukiko
Yamasaki, Masahiro
Tanaka, Hisashi
Takashima, Yuta
Soda, Sayo
Ishimoto, Osamu
Koyama, Nobuyuki
Kobayashi, Kunihiko
Takahashi, Kazuhisa
author_facet Mimori, Tomoyasu
Shukuya, Takehito
Ko, Ryo
Okuma, Yusuke
Koizumi, Tomonobu
Imai, Hisao
Takiguchi, Yuichi
Miyauchi, Eisaku
Kagamu, Hiroshi
Sugiyama, Tomohide
Azuma, Keisuke
Namba, Yukiko
Yamasaki, Masahiro
Tanaka, Hisashi
Takashima, Yuta
Soda, Sayo
Ishimoto, Osamu
Koyama, Nobuyuki
Kobayashi, Kunihiko
Takahashi, Kazuhisa
author_sort Mimori, Tomoyasu
collection PubMed
description SIMPLE SUMMARY: Advanced thymic carcinoma (ATC) is rare. Owing to its rarity, there is limited information on the prognostic factors, and the optimal serum tumor markers are also unknown. We conducted a multi-institutional retrospective study of patients with ATC. In this study, we collected data on patient characteristics, progression-free survival (PFS), overall survival (OS), and tumor marker values, and investigated the relationship between tumor marker values and PFS/OS. We found that the neuron-specific enolase (NSE) level may be a useful prognostic tumor marker for ATC, regardless of histology. The findings of the analysis limited to squamous cell carcinoma suggested that the NSE and squamous cell carcinoma antigen levels may be useful prognostic factors. ABSTRACT: The optimal tumor marker for predicting the prognosis of advanced thymic carcinoma (ATC) remains unclear. We conducted a multi-institutional retrospective study of patients with ATC. A total of 286 patients were treated with chemotherapy. Clinicopathological information, including serum tumor markers, was evaluated to determine the overall survival (OS) and progression-free survival (PFS). The carcinoembryonic antigen, cytokeratin-19 fragment, squamous cell carcinoma (SCC) antigen, progastrin-releasing peptide, neuron-specific enolase (NSE), and alpha-fetoprotein levels were evaluated. In the Kaplan–Meier analysis, the OS was significantly shorter in the patients with elevated NSE levels than in those with normal NSE levels (median, 20.3 vs. 36.8 months; log-rank test p = 0.029; hazard ratio (HR), 1.55; 95% confidence interval (CI), 1.05–2.31 (Cox proportional hazard model)); a similar tendency regarding the PFS was observed (median, 6.4 vs. 11.0 months; log-rank test p = 0.001; HR, 2.04; 95% CI, 1.31–3.18). No significant differences in the OS and PFS were observed among the other tumor markers. In both univariate and multivariate analyses of the patients with SCC only, the NSE level was associated with the OS and PFS. Thus, the NSE level may be a prognostic tumor marker for thymic carcinoma, regardless of histology.
format Online
Article
Text
id pubmed-8773938
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87739382022-01-21 Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study Mimori, Tomoyasu Shukuya, Takehito Ko, Ryo Okuma, Yusuke Koizumi, Tomonobu Imai, Hisao Takiguchi, Yuichi Miyauchi, Eisaku Kagamu, Hiroshi Sugiyama, Tomohide Azuma, Keisuke Namba, Yukiko Yamasaki, Masahiro Tanaka, Hisashi Takashima, Yuta Soda, Sayo Ishimoto, Osamu Koyama, Nobuyuki Kobayashi, Kunihiko Takahashi, Kazuhisa Cancers (Basel) Article SIMPLE SUMMARY: Advanced thymic carcinoma (ATC) is rare. Owing to its rarity, there is limited information on the prognostic factors, and the optimal serum tumor markers are also unknown. We conducted a multi-institutional retrospective study of patients with ATC. In this study, we collected data on patient characteristics, progression-free survival (PFS), overall survival (OS), and tumor marker values, and investigated the relationship between tumor marker values and PFS/OS. We found that the neuron-specific enolase (NSE) level may be a useful prognostic tumor marker for ATC, regardless of histology. The findings of the analysis limited to squamous cell carcinoma suggested that the NSE and squamous cell carcinoma antigen levels may be useful prognostic factors. ABSTRACT: The optimal tumor marker for predicting the prognosis of advanced thymic carcinoma (ATC) remains unclear. We conducted a multi-institutional retrospective study of patients with ATC. A total of 286 patients were treated with chemotherapy. Clinicopathological information, including serum tumor markers, was evaluated to determine the overall survival (OS) and progression-free survival (PFS). The carcinoembryonic antigen, cytokeratin-19 fragment, squamous cell carcinoma (SCC) antigen, progastrin-releasing peptide, neuron-specific enolase (NSE), and alpha-fetoprotein levels were evaluated. In the Kaplan–Meier analysis, the OS was significantly shorter in the patients with elevated NSE levels than in those with normal NSE levels (median, 20.3 vs. 36.8 months; log-rank test p = 0.029; hazard ratio (HR), 1.55; 95% confidence interval (CI), 1.05–2.31 (Cox proportional hazard model)); a similar tendency regarding the PFS was observed (median, 6.4 vs. 11.0 months; log-rank test p = 0.001; HR, 2.04; 95% CI, 1.31–3.18). No significant differences in the OS and PFS were observed among the other tumor markers. In both univariate and multivariate analyses of the patients with SCC only, the NSE level was associated with the OS and PFS. Thus, the NSE level may be a prognostic tumor marker for thymic carcinoma, regardless of histology. MDPI 2022-01-11 /pmc/articles/PMC8773938/ /pubmed/35053494 http://dx.doi.org/10.3390/cancers14020331 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mimori, Tomoyasu
Shukuya, Takehito
Ko, Ryo
Okuma, Yusuke
Koizumi, Tomonobu
Imai, Hisao
Takiguchi, Yuichi
Miyauchi, Eisaku
Kagamu, Hiroshi
Sugiyama, Tomohide
Azuma, Keisuke
Namba, Yukiko
Yamasaki, Masahiro
Tanaka, Hisashi
Takashima, Yuta
Soda, Sayo
Ishimoto, Osamu
Koyama, Nobuyuki
Kobayashi, Kunihiko
Takahashi, Kazuhisa
Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study
title Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study
title_full Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study
title_fullStr Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study
title_full_unstemmed Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study
title_short Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study
title_sort clinical significance of tumor markers for advanced thymic carcinoma: a retrospective analysis from the nej023 study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773938/
https://www.ncbi.nlm.nih.gov/pubmed/35053494
http://dx.doi.org/10.3390/cancers14020331
work_keys_str_mv AT mimoritomoyasu clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study
AT shukuyatakehito clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study
AT koryo clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study
AT okumayusuke clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study
AT koizumitomonobu clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study
AT imaihisao clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study
AT takiguchiyuichi clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study
AT miyauchieisaku clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study
AT kagamuhiroshi clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study
AT sugiyamatomohide clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study
AT azumakeisuke clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study
AT nambayukiko clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study
AT yamasakimasahiro clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study
AT tanakahisashi clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study
AT takashimayuta clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study
AT sodasayo clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study
AT ishimotoosamu clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study
AT koyamanobuyuki clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study
AT kobayashikunihiko clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study
AT takahashikazuhisa clinicalsignificanceoftumormarkersforadvancedthymiccarcinomaaretrospectiveanalysisfromthenej023study